… ProQR Announces Virtual Presentations at Scientific … Meeting of the American Academy of Optometry (AAOpt). ProQR’s presentation at Ophthalmology Futures Retina Forum … Leber congenital amaurosis 10 (LCA10) Presenter: Stephen R. Russell, MD, principal investigator of the ProQR Phase 1/2 …
… ProQR to Present at Upcoming Scientific Conferences … Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … be delivered by Aniz Girach, MD, Chief Medical Officer of ProQR, during the 3 rd Annual Ophthalmic Drugs Conference to …
… ProQR Announces Expert Perspectives Conference Call Series … & CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Drs. Girach and Koenekoop will also discuss QR-421a, ProQR’s investigational therapy for patients with Usher …
… ProQR to Present at Upcoming Investor Conferences … Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … will be accessible from the ‘Investors’ section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
LEIDEN, Netherlands, Sept. 18, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics today announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share.